Dr. Anil Potti is a United States based highly experienced clinician and Board Certified Oncologist who has gained popularity for providing empathetic care to patients with cancer. He attended the Christian Medical College & Hospital, Vellore, India and received his M.B.B.S. (Bachelor of Medicine & Surgery) degree in 1995. Dr. Potti has also worked for more than 4 years as a Staff Physician in the Multidisciplinary Thoracic Oncology Clinic, Duke University, Durham, NC. Owing to the dedicated services and thorough care provided to the patients, he has been awarded several times. He has won numerous awards like Alpha Omega Alpha (AOA), Outstanding Teacher of the Year Award – Medical students, Leonard P.Tow Humanism in Medicine Award, ASCO IDEA Mentor Award, Lisa Stafford Clinical Research Prize and more.
In 2010, Anil Potti MD won the Joseph Greenfield Mentoring Award from Duke University. This award is given to a faculty member from the Department of Medicine at Duke University who is nominated and chosen by internal medicine residents as someone who is an outstanding role-model, advocate, educator, and mentor for trainees/residents in internal medicine at Duke. In addition to this, he received the ASCO Merit Award in 2006. The ASCO Cancer Foundation Merit Awards are mainly given to promote clinical research carried out by young scientists and to provide fellows with an opportunity to present their research and interact with other clinical cancer investigators at ASCO scientific meetings. The ASCO Merit Award is annually given to Oncology fellows who are first authors on the abstracts that have been selected for presentation at an ASCO scientific meeting.
Dr. Anil Potti has also been an active part of a large number of programs in cancer. He has contributed in a large number of abstracts including Age-and-sex-specific genomic profiles in non-small cell lung cancer, Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma, Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential, Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. |
